NYX 2925

Drug Profile

NYX 2925

Alternative Names: NYX-2925

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aptinyx
  • Class Small molecules
  • Mechanism of Action Neurotransmitter modulators; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibromyalgia; Neuropathic pain
  • Phase I Neurological disorders

Most Recent Events

  • 14 Nov 2017 Pharmacodynamics data from preclinical studies in Neurological disorders presented at the 47th Annual Meeting of the Society for Neuroscience (SFN-2017)
  • 01 Aug 2017 Phase-II clinical trials in Fibromyalgia in USA (PO)
  • 14 Jun 2017 Phase-II clinical trials in Neuropathic pain (PO) in USA before June 2017 (NCT03219320)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top